Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.5362
-0.0557 (-9.41%)
Jun 25, 2025, 4:00 PM - Market closed
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$4,453,570
Market Cap
17.80M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RLMD News
- 9 days ago - Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology - GlobeNewsWire
- 6 weeks ago - Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - GlobeNewsWire
- 2 months ago - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GlobeNewsWire
- 2 months ago - Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - GlobeNewsWire
- 2 months ago - Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GlobeNewsWire